Ultragenyx Pharmaceutical RARE Enterprise value

Enterprise value at other companies

Eli LillyLLY

$1.12T+51.8%

AmgenAMGN

$252.17B+23.1%

Ionis PharmaceuticalsIONS

$13.02B+91.2%

Arrowhead ResearchARWR

$8.7B+418%

Zevra Therapeutics, Inc.ZVRA

$703.89M+36.7%

RegenxbioRGNX

$651.8M+51.8%

FAQ

What is Ultragenyx Pharmaceutical's enterprise value?

Ultragenyx Pharmaceutical (RARE) reported enterprise value of $1.83B in Q4 2025.

How has Ultragenyx Pharmaceutical's enterprise value changed year-over-year?

Ultragenyx Pharmaceutical's enterprise value decreased by 51.1% year-over-year, from $3.75B to $1.83B.

What is the long-term trend for Ultragenyx Pharmaceutical's enterprise value?

Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's enterprise value has grown at a -26.9% compound annual growth rate (CAGR), from $8.77B to $1.83B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.